Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. by Berger Montague on behalf of investors who traded Cepton shares during the specified Class Period, alleging undisclosed material information regarding a competing acquisition bid during the merger with Koito Manufacturing Co., Ltd. [1][3][4] Group 1: Lawsuit Details - The lawsuit claims that Cepton's senior executives failed to disclose a credible third-party acquisition bid that valued the company at more than double the price of the Koito merger proposal, which was valued at $3.17 per share [3][5]. - The Delaware Court of Chancery lawsuit indicates that Cepton's Board of Directors did not adequately explore the competing offer and did not disclose its terms when recommending the Koito transaction to shareholders [5][4]. - Investors became aware of the concealed material information after a redacted amended complaint was made public in September 2025, revealing that the proxy materials for the Koito acquisition lacked transparency [4][5]. Group 2: Company Background - Cepton, Inc. is a lidar technology company based in San Jose, California, and was acquired by Koito Manufacturing Co., Ltd. in January 2025, after which its stock is no longer publicly traded [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific claims include that Baxter was aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5]. - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging significant accounting irregularities and misleading disclosures that resulted in inflated profits and concealed losses [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Marex shares between May 16, 2024, and August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff [2]. - The lawsuit follows a report from NINGI Research that accused Marex of engaging in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions [3][4]. Group 2: Allegations and Financial Discrepancies - The report highlighted multi-million-dollar discrepancies in intercompany receivables and loans, including a fabricated $17 million receivable and a subsidiary's profits inflated by 150% [4]. - It was alleged that Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure, which was used to generate non-cash trading profits [4]. Group 3: Market Reaction - Following the report's release, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31, indicating significant investor losses [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific claims include that Baxter was aware of multiple device malfunctions and that its remedial measures were inadequate, resulting in a heightened risk of product recalls and sales pauses [5] - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, causing investor damages when the truth was revealed [5]

Core Points - A class action lawsuit has been filed against Marex Group plc on behalf of investors who purchased shares between May 16, 2024, and August 5, 2025 [1][2] - The lawsuit follows a report by NINGI Research that alleged financial improprieties, including a multi-year accounting scheme and misleading disclosures [3][4] - Marex is accused of concealing nearly $1 billion in off-balance-sheet derivatives, which inflated profits and operating cash flow [4] Company Overview - Marex Group plc is headquartered in London and provides global financial services, including trading, clearing, and risk management [2] Allegations and Impact - The complaint details discrepancies in intercompany receivables and loans across over 56 entities, amounting to multi-million-dollar discrepancies [3] - Following the release of the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [4]

Core Viewpoint - A class action lawsuit has been filed against Sina Corporation, alleging that the company artificially depressed its share value during its go-private merger, impacting shareholders' ability to make informed decisions [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who sold Sina shares between October 13, 2020, and March 22, 2021, including those who sold during the go-private merger [1][2]. - Investors have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit claims that critical information was withheld from proxy materials, which shareholders needed to make informed decisions [3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants concealed the true value of Sina's investment in TuSimple, leading to a cash consideration that substantially undervalued the shares [4]. - Internal documents revealed during a related shareholder appraisal proceeding indicated that senior executives knowingly hid the investment's true value, resulting in shareholders receiving less than the worth of their shares at the transaction's closing [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Dow Inc. securities between January 30, 2025, and July 23, 2025, of the upcoming lead plaintiff deadline on October 28, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Dow securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 28, 2025 [2]. - The lawsuit alleges that Dow made false and misleading statements regarding its financial flexibility and the impact of macroeconomic factors on its business [4]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in handling significant cases [3].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (NYSE: FLR) by Berger Montague on behalf of investors who acquired shares between February 18, 2025, and July 31, 2025, alleging that the company misled investors regarding its financial guidance and undisclosed risks associated with major infrastructure projects [1][3]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally. Its Urban Solutions segment is the largest revenue contributor among its three segments [2]. Lawsuit Details - The lawsuit claims that Fluor and certain executives failed to disclose rising costs related to significant projects, including the Gordie Howe, I-635/LBJ, and I-35 projects, which were impacted by subcontractor design errors, material price increases, and scheduling delays. Additionally, the company allegedly downplayed the adverse effects of reduced client capital spending and broader economic uncertainties [3]. Financial Guidance - In February 2025, Fluor projected an adjusted EPS for the full year 2025 in the range of $2.25 to $2.75 and EBITDA between $575 million and $675 million, which was reaffirmed in May 2025 [4]. Recent Performance - On August 1, 2025, Fluor reported disappointing second-quarter results, with non-GAAP EPS of $0.43, missing consensus estimates by 23%, and revenue of $3.98 billion, falling short by $570 million and down 5.9% year-over-year. The company significantly lowered its FY 2025 outlook, attributing the decline to project delays and reduced client awards. CEO James R. Breuer confirmed that the aforementioned projects were responsible for the poor performance. Following this announcement, Fluor's stock price dropped by $15.35, or 27.04%, closing at $41.42 [5].

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. by Berger Montague on behalf of investors who traded Cepton shares during the specified Class Period, alleging failure to disclose a competing acquisition bid during the merger approval process with Koito Manufacturing Co., Ltd. [1][3][4] Company Overview - Cepton, Inc. is a lidar technology company based in San Jose, California, and was acquired by Koito Manufacturing Co., Ltd. in January 2025, after which its stock is no longer publicly traded [2]. Allegations of the Lawsuit - The lawsuit claims that Cepton's management did not disclose a credible third-party acquisition bid that valued the company at more than double the $3.17 per share offered by Koito during the merger approval process [3][5]. - It is alleged that Cepton's Board of Directors failed to adequately explore the competing offer and did not disclose its terms, which deprived shareholders of a fair opportunity to evaluate the proposed deal [5]. Legal Proceedings - Following the merger, former shareholders initiated a lawsuit against Cepton's senior officers in the Delaware Court of Chancery, revealing that proxy materials for the Koito acquisition concealed significant information from shareholders [4][5].

Core Viewpoint - A class action lawsuit has been filed against Sina Corporation by Berger Montague on behalf of investors who sold shares during the specified Class Period, alleging that the company engaged in a fraudulent scheme to undervalue its shares during a go-private transaction [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who sold Sina shares from October 13, 2020, to March 22, 2021, and they have until November 18, 2025, to seek lead plaintiff status [2]. - The allegations include that the defendants concealed the true value of Sina's investment in TuSimple, leading to a cash offer that significantly undervalued the company's shares [3][4]. Group 2: Company Background - Sina Corporation is a global digital media company based in Beijing, China, providing online platforms for news, social media, entertainment, and financial content [2]. - The lawsuit claims that senior executives were aware of the true value of the investment but chose to conceal it, resulting in shareholders receiving less than the actual worth of their shares during the transaction [4].